China Pharma Holdings, Inc. (CPHI) News
Filter CPHI News Items
CPHI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CPHI News From Around the Web
Below are the latest news stories about CHINA PHARMA HOLDINGS INC that investors may wish to consider to help them evaluate CPHI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off Monday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on! |
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock SplitChina Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol "CPHI". The new CUSIP number for the common stock following the reverse stock split is 16941T-203. |
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective MaskChina Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask"). |
China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, trader! |
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device ProjectChina Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the Acquisition of Dry Eye Disease Therapeutic Device Project. |
China Pharma Announces Receipt of Noncompliance Notice from NYSE AmericanChina Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on December 1, 2022, received a notification (the "Deficiency Letter") from the NYSE American LLC (the "NYSE American") stating that the Company was not in compliance with a certain NYSE American continued listing standard relating to stockholders' equity, or Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer to have sto |
China Pharma Announces Receipt of Notification of NYSE American Listing DeficiencyChina Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Deficiency Letter") from the NYSE AMERICAN LLC ("NYSE American") informing it that the Company is not in compliance with certain NYSE American continued listing standards (the "Listing Standards"). The Deficiency Letter indicated that the Company's securities had been selling for a low price per share for a substantial period of time and, most recen |
China Pharma Announced the Submission of a Plan of Compliance to NYSE AmericanChina Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on July 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the "Exchange") to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022 (the "Letter"). |